<DOC>
	<DOC>NCT00638053</DOC>
	<brief_summary>The purpose of this study is to assess the prevalence of GHD in patients who sustain a head injury or suffer a major traumatic event and to evaluate the efficacy of growth hormone (GH) therapy in the treatment of GHD caused by trauma or head injury</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury</brief_title>
	<detailed_description>The study was terminated on October 9, 2003. The reason cited for the termination was due to poor patient recruitment and therefore not enough data could be collected to provide comprehensive analysis for reporting of results. No safety or efficacy issues were reported to cause the termination of the study.</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Craniocerebral Trauma</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Documented GHD Documented mild, moderate, and severe head injury (e.g.,Glasgow COMA Scale score less than or equal to 15 or equivalent measure) Active systemic malignancy or active intracranial tumor Growth hormone replacement therapy in the last 12 months History of dementia unrelated to traumatic brain injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>